Our top pick for
Genworth Financial, Inc is an insurance-life business based in the US. Genworth Financial shares (GNW) are listed on the NYSE and all prices are listed in US Dollars. Genworth Financial employs 3,000 staff and has a trailing 12-month revenue of around USD$8.7 billion.
|52-week range||USD$1.95 - USD$4.76|
|50-day moving average||USD$3.3167|
|200-day moving average||USD$3.6221|
|Wall St. target price||USD$2.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.347|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Genworth Financial stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genworth Financial's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Genworth Financial's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Genworth Financial shares trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Genworth Financial's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.72. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Genworth Financial's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Genworth Financial's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1.3 billion.
The EBITDA is a measure of a Genworth Financial's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$8.7 billion|
|Operating margin TTM||14.3%|
|Gross profit TTM||USD$1.2 billion|
|Return on assets TTM||0.75%|
|Return on equity TTM||5%|
|Market capitalisation||USD$1.6 billion|
TTM: trailing 12 months
There are currently 12.0 million Genworth Financial shares held short by investors – that's known as Genworth Financial's "short interest". This figure is 9.8% down from 13.3 million last month.
There are a few different ways that this level of interest in shorting Genworth Financial shares can be evaluated.
Genworth Financial's "short interest ratio" (SIR) is the quantity of Genworth Financial shares currently shorted divided by the average quantity of Genworth Financial shares traded daily (recently around 8.7 million). Genworth Financial's SIR currently stands at 1.38. In other words for every 100,000 Genworth Financial shares traded daily on the market, roughly 1380 shares are currently held short.
However Genworth Financial's short interest can also be evaluated against the total number of Genworth Financial shares, or, against the total number of tradable Genworth Financial shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genworth Financial's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Genworth Financial shares in existence, roughly 20 shares are currently held short) or 0.0272% of the tradable shares (for every 100,000 tradable Genworth Financial shares, roughly 27 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genworth Financial.
Find out more about how you can short Genworth Financial stock.
We're not expecting Genworth Financial to pay a dividend over the next 12 months.
Over the last 12 months, Genworth Financial's shares have ranged in value from as little as $1.95 up to $4.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Genworth Financial's is 0.9813. This would suggest that Genworth Financial's shares are less volatile than average (for this exchange).
Genworth Financial, Inc. provides insurance products in the United States and internationally. It operates through four segments: U.S. Mortgage Insurance, Australia Mortgage Insurance, U.S. Life Insurance, and Runoff. The U.S. Mortgage Insurance segment offers mortgage insurance products primarily insuring prime-based, individually underwritten residential mortgage loans. The Australia Mortgage Insurance segment offers flow mortgage insurance and bulk mortgage insurance that aids in the sale of mortgages to the capital markets and helps lenders manage capital and risk. The U.S. Life Insurance segment offers long-term care insurance products; and service traditional life insurance and fixed annuity products in the United States. The Runoff segment includes variable annuity, variable life insurance, and corporate-owned life insurance, as well as funding agreements. The company distributes its products and services through employer groups and directly to customers through its internal sales team. Genworth Financial, Inc. was founded in 1871 and is headquartered in Richmond, Virginia.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.